Prana Biotechnology has developed a proprietary library of class-leading chemical compounds. This library is combined with a drug development program to explore novel therapeutics in multiple disease indications. The scientific focus of the company is upon neurological diseases, particularly Alzheimer‘s, Parkinson‘s and Huntington‘s diseases.

The company listed on the Australian Stock Exchange (ASX code PBT) in March 2000 and listed on the NASDAQ (code PRAN) in September 2002.